Ken Griffin Chinook Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2023

Aug 14, 2023
BUY
$18.66 - $38.58 $171,672 - $354,936
9,200 Added 204.44%
13,700 $526,000
Q1 2023

May 15, 2023
SELL
$21.53 - $26.8 $36,601 - $45,560
-1,700 Reduced 27.42%
4,500 $104,000
Q4 2022

Feb 14, 2023
SELL
$18.63 - $27.35 $4.73 Million - $6.95 Million
-254,000 Reduced 97.62%
6,200 $162,000
Q3 2022

Nov 14, 2022
SELL
$17.51 - $23.37 $800,207 - $1.07 Million
-45,700 Reduced 14.94%
260,200 $5.12 Million

Others Institutions Holding KDNY

# of Institutions
5
Shares Held
234K
Call Options Held
0
Put Options Held
0
View Full List

About CHINOOK THERAPEUTICS, INC.

KDNY Quotes by TradingView
  • Ticker KDNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,896,300
  • Description
  • Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...
More about KDNY
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email